The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.
John Henry McDermottMarc LeachDwaipayan SenCraig J SmithWilliam G NewmanPhilip M BathPublished in: Expert review of clinical pharmacology (2022)
LoF allele carriers of Han-Chinese ancestry have increased risk for further vascular events following TIA or IS when treated with clopidogrel. The evidence base is less certain in other populations. The expansion of pharmacogenetics into routine clinical practice will facilitate further research and help tailor other aspects of secondary prevention.
Keyphrases
- antiplatelet therapy
- clinical practice
- acute coronary syndrome
- percutaneous coronary intervention
- cerebral ischemia
- genetic diversity
- atrial fibrillation
- high throughput
- genome wide
- subarachnoid hemorrhage
- ischemia reperfusion injury
- brain injury
- blood brain barrier
- genome wide association study
- gene expression
- single cell